The spinal cord injury-induced immune deficiency syndrome: results of the SCIentinel study.
MHC class II
host defense
major histocompatibility complex class II
neurogenic immune suppression
Journal
Brain : a journal of neurology
ISSN: 1460-2156
Titre abrégé: Brain
Pays: England
ID NLM: 0372537
Informations de publication
Date de publication:
01 08 2023
01 08 2023
Historique:
received:
04
03
2022
revised:
13
01
2023
accepted:
29
01
2023
medline:
3
8
2023
pubmed:
28
6
2023
entrez:
27
6
2023
Statut:
ppublish
Résumé
Infections are prevalent after spinal cord injury (SCI), constitute the main cause of death and are a rehabilitation confounder associated with impaired recovery. We hypothesize that SCI causes an acquired lesion-dependent (neurogenic) immune suppression as an underlying mechanism to facilitate infections. The international prospective multicentre cohort study (SCIentinel; protocol registration DRKS00000122; n = 111 patients) was designed to distinguish neurogenic from general trauma-related effects on the immune system. Therefore, SCI patient groups differing by neurological level, i.e. high SCI [thoracic (Th)4 or higher]; low SCI (Th5 or lower) and severity (complete SCI; incomplete SCI), were compared with a reference group of vertebral fracture (VF) patients without SCI. The primary outcome was quantitative monocytic Human Leukocyte Antigen-DR expression (mHLA-DR, synonym MHC II), a validated marker for immune suppression in critically ill patients associated with infection susceptibility. mHLA-DR was assessed from Day 1 to 10 weeks after injury by applying standardized flow cytometry procedures. Secondary outcomes were leucocyte subpopulation counts, serum immunoglobulin levels and clinically defined infections. Linear mixed models with multiple imputation were applied to evaluate group differences of logarithmic-transformed parameters. Mean quantitative mHLA-DR [ln (antibodies/cell)] levels at the primary end point 84 h after injury indicated an immune suppressive state below the normative values of 9.62 in all groups, which further differed in its dimension by neurological level: high SCI [8.95 (98.3% confidence interval, CI: 8.63; 9.26), n = 41], low SCI [9.05 (98.3% CI: 8.73; 9.36), n = 29], and VF without SCI [9.25 (98.3% CI: 8.97; 9.53), n = 41, P = 0.003]. Post hoc analysis accounting for SCI severity revealed the strongest mHLA-DR decrease [8.79 (95% CI: 8.50; 9.08)] in the complete, high SCI group, further demonstrating delayed mHLA-DR recovery [9.08 (95% CI: 8.82; 9.38)] and showing a difference from the VF controls of -0.43 (95% CI: -0.66; -0.20) at 14 days. Complete, high SCI patients also revealed constantly lower serum immunoglobulin G [-0.27 (95% CI: -0.45; -0.10)] and immunoglobulin A [-0.25 (95% CI: -0.49; -0.01)] levels [ln (g/l × 1000)] up to 10 weeks after injury. Low mHLA-DR levels in the range of borderline immunoparalysis (below 9.21) were positively associated with the occurrence and earlier onset of infections, which is consistent with results from studies on stroke or major surgery. Spinal cord injured patients can acquire a secondary, neurogenic immune deficiency syndrome characterized by reduced mHLA-DR expression and relative hypogammaglobulinaemia (combined cellular and humoral immune deficiency). mHLA-DR expression provides a basis to stratify infection-risk in patients with SCI.
Identifiants
pubmed: 37370200
pii: 7204299
doi: 10.1093/brain/awad092
pmc: PMC10393404
doi:
Substances chimiques
HLA-DR Antigens
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
3500-3512Subventions
Organisme : ACL HHS
ID : 90SI5020
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS118200
Pays : United States
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the Guarantors of Brain.
Références
Crit Care. 2020 Mar 20;24(1):110
pubmed: 32192532
Sci Rep. 2022 Jul 6;12(1):11420
pubmed: 35794189
J Neurosci. 2013 Aug 7;33(32):12970-81
pubmed: 23926252
Am J Phys Med Rehabil. 1994 Nov-Dec;73(6):387-93
pubmed: 7993612
Exp Neurol. 2010 Nov;226(1):242-53
pubmed: 20832407
Nat Neurosci. 2016 Jun;19(6):784-7
pubmed: 27089020
Exp Neurol. 2007 Sep;207(1):75-84
pubmed: 17597612
Spinal Cord. 2020 Aug;58(8):873-881
pubmed: 32071433
Cochrane Database Syst Rev. 2012 Jan 18;1:CD001046
pubmed: 22258943
Eur J Neurol. 2009 Apr;16(4):498-505
pubmed: 19187263
Br J Anaesth. 2000 Jul;85(1):109-17
pubmed: 10927999
BMC Neurol. 2013 Nov 09;13:168
pubmed: 24206943
Intensive Care Med. 2018 Nov;44(11):1836-1848
pubmed: 30291379
Clin Transl Med. 2021 Jan;11(1):e272
pubmed: 33463065
Curr Opin Hematol. 2005 Jan;12(1):22-30
pubmed: 15604887
Eur J Neurosci. 2007 Mar;25(6):1743-7
pubmed: 17432962
Nat Rev Neurosci. 2005 Oct;6(10):775-86
pubmed: 16163382
Respir Physiol Neurobiol. 2009 May 15;166(3):129-41
pubmed: 19442929
Stroke. 2011 Jan;42(1):53-8
pubmed: 21088239
Intensive Care Med. 2006 Aug;32(8):1175-83
pubmed: 16741700
Intensive Care Med. 2010 Nov;36(11):1859-66
pubmed: 20652682
Exp Neurol. 2015 Sep;271:46-52
pubmed: 25959599
Spinal Cord. 2010 Mar;48(3):197-201
pubmed: 19668256
J Neurotrauma. 2018 Aug 1;35(15):1819-1829
pubmed: 29310515
Brain. 2016 Mar;139(Pt 3):692-707
pubmed: 26754788
Pathobiology. 1993;61(3-4):183-92
pubmed: 8216840
Nat Commun. 2020 Jul 24;11(1):3702
pubmed: 32710081
Crit Care. 2016 Oct 20;20(1):334
pubmed: 27760554
J Neurotrauma. 2019 Nov 1;36(21):3044-3050
pubmed: 31007137
J Spinal Cord Med. 2011 Nov;34(6):547-54
pubmed: 22330109
Neurology. 2017 Feb 28;88(9):892-900
pubmed: 28130472
Respir Physiol Neurobiol. 2009 Nov 30;169(2):157-64
pubmed: 19682607
Arch Phys Med Rehabil. 1999 Nov;80(11):1411-9
pubmed: 10569435
Biom J. 2008 Jun;50(3):346-63
pubmed: 18481363
Lancet Infect Dis. 2019 Dec;19(12):e422-e436
pubmed: 31630991
Br J Surg. 1993 Feb;80(2):205-9
pubmed: 8443652
Neuroscience. 2009 Feb 6;158(3):1194-9
pubmed: 18790013
Clin Chest Med. 2018 Jun;39(2):411-425
pubmed: 29779599
Clin Chem. 2005 Dec;51(12):2341-7
pubmed: 16214828
Cytometry B Clin Cytom. 2003 May;53(1):54-62
pubmed: 12717692
Nat Neurosci. 2017 Nov;20(11):1549-1559
pubmed: 28920935
Spinal Cord. 2009 Feb;47(2):122-7
pubmed: 18663374
Crit Care. 2010;14(6):R208
pubmed: 21092108
J Spinal Cord Med. 2022 Sep;45(5):728-738
pubmed: 33443466
Ann Intensive Care. 2022 May 8;12(1):39
pubmed: 35526199
J Cereb Blood Flow Metab. 2017 Dec;37(12):3671-3682
pubmed: 27733675
Brain. 2012 Nov;135(Pt 11):3238-50
pubmed: 23100450
J Clin Med. 2021 Dec 24;11(1):
pubmed: 35011836
BMC Neurol. 2016 Sep 13;16:170
pubmed: 27618987